- Home
- PLX vs SRG Comparison
PLX vs SRG Comparison
Compare PLX & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- SRG
- Stock Information
- Founded
- PLX 1993
- SRG 2014
- Country
- PLX United States
- SRG United States
- Employees
- PLX N/A
- SRG N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- SRG Real Estate Investment Trusts
- Sector
- PLX Health Care
- SRG Real Estate
- Exchange
- PLX Nasdaq
- SRG Nasdaq
- Market Cap
- PLX 160.2M
- SRG 163.3M
- IPO Year
- PLX 1998
- SRG 2015
- Fundamental
- Price
- PLX $1.58
- SRG $2.76
- Analyst Decision
- PLX Strong Buy
- SRG
- Analyst Count
- PLX 1
- SRG 0
- Target Price
- PLX $15.00
- SRG N/A
- AVG Volume (30 Days)
- PLX 1.4M
- SRG 122.6K
- Earning Date
- PLX 05-09-2025
- SRG 05-15-2025
- Dividend Yield
- PLX N/A
- SRG N/A
- EPS Growth
- PLX N/A
- SRG N/A
- EPS
- PLX 0.05
- SRG N/A
- Revenue
- PLX $59,764,000.00
- SRG N/A
- Revenue This Year
- PLX $65.02
- SRG N/A
- Revenue Next Year
- PLX $57.34
- SRG N/A
- P/E Ratio
- PLX $32.18
- SRG N/A
- Revenue Growth
- PLX 0.18
- SRG N/A
- 52 Week Low
- PLX $0.82
- SRG $2.43
- 52 Week High
- PLX $3.10
- SRG $5.52
- Technical
- Relative Strength Index (RSI)
- PLX 30.32
- SRG 37.10
- Support Level
- PLX $1.52
- SRG $2.81
- Resistance Level
- PLX $1.79
- SRG $2.91
- Average True Range (ATR)
- PLX 0.09
- SRG 0.09
- MACD
- PLX -0.01
- SRG -0.01
- Stochastic Oscillator
- PLX 26.44
- SRG 17.14
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.